CFDE Data Portal | Search RPS27AP4

	Label	Description
	RPS27AP4 Gene (Entity type)	ENSG00000258932 - RPS27A pseudogene 4
	GSE195663 cisplatin 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 6 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE110709 GSK-J4 5 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 8 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE171988 MBNL knockout Schneider 1 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE213410 calcitriol 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 4 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE117620 resveratrol 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

RPS27AP4

ENSG00000258932 - RPS27A pseudogene 4

GSE195663 cisplatin 0 v 3 human dn

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 6 v 10 human dn

A Gene Set from LINCS

GSE110709 GSK-J4 5 v 4 human dn

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 8 v 0 human dn

A Gene Set from LINCS

GSE171988 MBNL knockout Schneider 1 1 v 3 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 3 human dn

A Gene Set from LINCS

GSE213410 calcitriol 2 v 3 human dn

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 4 v 7 human up

A Gene Set from LINCS

GSE117620 resveratrol 1 v 3 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.